US EditionImperative Care’s Stroke and Vascular Thrombectomy Portfolio Supported by New Financing
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Imperative Care’s Stroke and Vascular Thrombectomy Portfolio Supported by New Financing
March 18, 2026—Imperative Care, Inc., a developer of treatments for thromboembolic disease, announced the closing of a $100 million convertible note financing. According to the company, the proceeds from the financing will support the continued commercialization of Imperative Care’s stroke and vascular thrombectomy portfolios. Proceeds will also be used for investments in next-generation and new product development—including the Telos robotic pl…
Imperative Care Announces $100 Million Financing
Funding supports continued growth and innovation in thromboembolic disease careCAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, t... L'articolo Imperative Care Announces $100 Million Financing è un contenuto originale di 01net.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
